(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 December 2012 (06.12.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/165915 A2

(51) International Patent Classification:
A61K 47/48 (2006.01) *A61K 47/30* (2006.01)
A61K 38/28 (2006.01) *A61P 3/10* (2006.01)

(21) International Application Number:
PCT/KR2012/004367

(22) International Filing Date:
1 June 2012 (01.06.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10-2011-0053488 2 June 2011 (02.06.2011) KR

(71) Applicant *(for all designated States except US)*: **HANMI SCIENCE CO., LTD.** [KR/KR]; 550, Dongtangi-heung-ro, Dongtan-myeon, Hwaseong-si, Gyeonggi-do 445-813 (KR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **WOO, Young Eun** [KR/KR]; 106-1307, Nuri Apt., Wolpyeong 3-dong, Seo-gu, Daejeon 302-791 (KR). **JANG, Myung Hyun** [KR/KR]; 137-2403, Lotte Castle First Apt., Amsa 3-dong, Gangdong-gu, Seoul 134-716 (KR). **PARK, Young Jin** [KR/KR]; 506-501, Sinnamusil Jugong Apt., Yeong-tong-dong, Yeongtong-gu, Suwon-si, Gyeonggi-do 443-470 (KR). **PARK, Young Kyung** [KR/KR]; 921-105, Dongtan Pureun Maeul Doosan Weve Apt., Neung-dong, Hwaseong-si, Gyeonggi-do 445-799 (KR). **LIM, Chang Ki** [KR/KR]; 207-904, Sinyeongtong Hyundai 2 Cha Apt., Banwol-dong, Hwaseong-si, Gyeonggi-do 445-983 (KR). **KWON, Se Chang** [KR/KR]; 10-1204, Kukdong Apt., Gwangjang-dong, Gwangjin-gu, Seoul 143-751 (KR).

(74) Agent: **SON, Min**; Hanol Intellectual Property & Law, 6th Floor, City Air Tower, 36, Teheran-ro 87 gil, Sam-sung-dong, Gangnam-gu, Seoul 135-973 (KR).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: COMPOSITION FOR TREATING DIABETES COMPRISING LONG-ACTING INSULIN CONJUGATE AND LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE

[Fig. 1]



(57) Abstract: The present invention relates to a composition for the prevention or treatment of diabetes comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a therapeutic method for the treatment of diabetes, and more particularly, concurrent administration of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain caused by insulin treatment, and vomiting and nausea caused by insulinotropic peptide treatment, and reduces the required dose of insulin, thereby remarkably improving drug compliance. Moreover, each of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate of the present invention is prepared by linking insulin or insulinotropic peptide with an immunoglobulin Fc region via a non-peptidyl linker, thereby showing improved *in-vivo* duration of efficacy and stability.

WO 2012/165915 A2

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*